CYTOSORBENTS CORPORATION Adjustments to Additional Paid in Capital, Warrant Issued
CYTOSORBENTS CORPORATION (CTSO) reported Adjustments to Additional Paid in Capital, Warrant Issued of $627.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-03-30
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $291.00.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, warrant issued for the quarter ending 2024-09-30 was $0.00.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, warrant issued for the quarter ending 2024-06-30 was $690.71K.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, warrant issued for fiscal 2025 was $627.00K, a 9.26% decline from fiscal 2024.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, warrant issued for fiscal 2024 was $691.00K.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, warrant issued for fiscal 2009 was $14.88K, a 63.11% decline from fiscal 2008.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, warrant issued for fiscal 2008 was $40.35K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $627.00K 10-K · filed 2026-03-30 | ||||
| 2024-12-31 | $291.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $291.00 derived: sum of 2 quarters · filed 2026-03-30 | $691.00K derived: sum of 3 quarters · filed 2026-03-30 | $691.00K 10-K · filed 2026-03-30 | $690.71K 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $690.71K derived: sum of 2 quarters · filed 2024-11-07 | $690.71K 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | $690.71K 10-Q · filed 2024-08-13 | $690.71K 10-Q · filed 2024-08-13 | |||
| 2009-12-31 | $14.88K 10-K · filed 2012-03-30 | ||||
| 2008-12-31 | $40.35K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |